Search
MEM 1003
go.drugbank.com/drugs/DB05547InvestigationalMEM 10003 was under investigation in clinical trial NCT00257673 (Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease) for the treatment of Alzheimer's Disease
Gabexate
go.drugbank.com/drugs/DB12831InvestigationalGabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220] … Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines.
ATG-Fresenius S
go.drugbank.com/drugs/DB05320InvestigationalATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. … ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line.
Mexazolam
go.drugbank.com/drugs/DB15489Investigational[A184910] The use of benzodiazepines in the treatment of anxiety is generally a second line measure.[A184910] … [A184910] Mexazolam's structure is similar to that of other benzodiazepines such as [oxazolam] and [cloxazolam].
BZL101
go.drugbank.com/drugs/DB05051InvestigationalBZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Polydatin
go.drugbank.com/drugs/DB11263ApprovedWhile it is isolated from the bark of *Picea sitchensis* or *Polygonum cuspidatum*, polydatin may be detected in grape, peanut, hop cones, red wines, hop pellets, cocoa-containing products, chocolate products … It is shown to mediate a cytotoxic action on colorectal cancer cells by inducing cell arrest and apoptosis [A27229].
VTP-201227
go.drugbank.com/drugs/DB05652ExperimentalIt is being developed by Vitae Pharmaceuticals. … VTP-201227 has a novel mechanism of action and is being developed as a topical agent for the treatment of psoriasis with potential extensions into other dermatological indications.
BIIB015
go.drugbank.com/drugs/DB06304InvestigationalBIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.